ZA200207769B - A nucleic acid construct encoding a processing component derived from the N-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide. - Google Patents

A nucleic acid construct encoding a processing component derived from the N-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide. Download PDF

Info

Publication number
ZA200207769B
ZA200207769B ZA200207769A ZA200207769A ZA200207769B ZA 200207769 B ZA200207769 B ZA 200207769B ZA 200207769 A ZA200207769 A ZA 200207769A ZA 200207769 A ZA200207769 A ZA 200207769A ZA 200207769 B ZA200207769 B ZA 200207769B
Authority
ZA
South Africa
Prior art keywords
nucleic acid
processing component
seq
sequence
processing
Prior art date
Application number
ZA200207769A
Other languages
English (en)
Inventor
Fan Li
Damian Francis John Purcell
David Andrew Anderson
Original Assignee
Macfarlane Burnet Inst For Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macfarlane Burnet Inst For Med filed Critical Macfarlane Burnet Inst For Med
Publication of ZA200207769B publication Critical patent/ZA200207769B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
ZA200207769A 2000-03-31 2002-09-26 A nucleic acid construct encoding a processing component derived from the N-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide. ZA200207769B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPQ6616A AUPQ661600A0 (en) 2000-03-31 2000-03-31 A nucleic acid construct and methods related thereto

Publications (1)

Publication Number Publication Date
ZA200207769B true ZA200207769B (en) 2004-02-10

Family

ID=3820712

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200207769A ZA200207769B (en) 2000-03-31 2002-09-26 A nucleic acid construct encoding a processing component derived from the N-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide.

Country Status (14)

Country Link
US (1) US7341723B2 (cg-RX-API-DMAC7.html)
EP (1) EP1274851B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003528614A (cg-RX-API-DMAC7.html)
KR (1) KR100768051B1 (cg-RX-API-DMAC7.html)
CN (1) CN1426472A (cg-RX-API-DMAC7.html)
AT (1) ATE430804T1 (cg-RX-API-DMAC7.html)
AU (1) AUPQ661600A0 (cg-RX-API-DMAC7.html)
CA (1) CA2407036A1 (cg-RX-API-DMAC7.html)
DE (1) DE60138612D1 (cg-RX-API-DMAC7.html)
HK (1) HK1052368A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA02009437A (cg-RX-API-DMAC7.html)
NZ (1) NZ521758A (cg-RX-API-DMAC7.html)
WO (1) WO2001073078A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200207769B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
MXPA05000287A (es) 2002-07-05 2005-09-08 Leclerc Denis Particula viral adyuvante.
KR100641810B1 (ko) * 2004-04-23 2006-11-06 주식회사 포스코건설 충격흡수 및 복원 가능한 중간 스프링 설치 금속재 지주
US8906863B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
US8906862B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Multiple antigen delivery system using hepatitis E virus-like particle
WO2010099547A1 (en) * 2009-02-27 2010-09-02 The Regents Of The University Of California Multiple antigen delivery system using hepatitis e virus-like particle

Also Published As

Publication number Publication date
JP2003528614A (ja) 2003-09-30
ATE430804T1 (de) 2009-05-15
AUPQ661600A0 (en) 2000-05-04
KR20030015223A (ko) 2003-02-20
EP1274851A1 (en) 2003-01-15
MXPA02009437A (es) 2006-05-25
EP1274851B1 (en) 2009-05-06
WO2001073078A1 (en) 2001-10-04
KR100768051B1 (ko) 2007-10-18
EP1274851A4 (en) 2004-12-08
US7341723B2 (en) 2008-03-11
CN1426472A (zh) 2003-06-25
DE60138612D1 (de) 2009-06-18
NZ521758A (en) 2004-05-28
HK1052368A1 (zh) 2003-09-11
CA2407036A1 (en) 2001-10-04
US20030158138A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
KR102945692B1 (ko) 아프리카 돼지 열병 바이러스 백신
DiMarchi et al. Protection of cattle against foot-and-mouth disease by a synthetic peptide
AU2018232999B2 (en) Synthetic peptide-based emergency vaccine against foot and mouth disease (FMD)
EP2057268B1 (en) A dna vaccine for curing chronic hepatitis b and a method of preparing same
Zheng et al. Construction and immunogenicity of a recombinant fowlpox virus containing the capsid and 3C protease coding regions of foot-and-mouth disease virus
KR20230005265A (ko) Sars-cov-2에 대한 백신 및 이의 제조
US20040223977A1 (en) Fusion peptide HIV vaccines
Mingxiao et al. Immunogenicity of plasmids encoding P12A and 3C of FMDV and swine IL-18
US7341723B2 (en) Nucleic acid construct encoding a processing component derived from the N-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide
US8183358B2 (en) Puumala virus full-length M segment-based DNA vaccines
JP2010279361A (ja) Hiv抗原およびサイトカインをコードする禽痘ベクター
JPH10503649A (ja) ポリヌクレオチド・ヘルペスウイルス・ワクチン
AU2001243941B2 (en) A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide
AU2001243941A1 (en) A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide
KR20240109612A (ko) 세포 막에서 항원을 발현시키기 위한 조성물 및 방법
CA2370278C (en) Chimeric lyssavirus nucleic acids and polypeptides
KR100689249B1 (ko) Hiv 백신
KR20110060865A (ko) 리슈마니아증 및 결핵에 대한 백신 개발을 위한 dna 키메라의 작제
US20150274784A1 (en) Production of an Immunogen Using a Plant Virus
WO2022149609A1 (ja) Mhc分子に適合する病原微生物由来のペプチドが担持された複合蛋白質単量体、当該単量体の会合体、及び当該会合体を有効成分とするコンポーネントワクチン、並びに、免疫後の生理活性物質の分泌に関する情報の取得方法
US20160215023A1 (en) Simple vaccines from dna launched suicidal flaviviruses
EP1721982B1 (en) Chimeric lyssavirus nucleic acids and polypeptides
WO2020014013A1 (en) Viral-vectored vaccine for malaria